" class="no-js "lang="en-US"> CRISPR QC Co-founder Kiana Aran Makes Female Founders List
Wednesday, June 19, 2024

CRISPR QC Co-founder Kiana Aran Makes Inc.’s 2023 Female Founders List

CRISPR QC is proud to announce that co-founder Kiana Aran has been recognized by Inc. magazine as a top 200 Female Founder. This prestigious list highlights women entrepreneurs who are making a significant impact in their respective industries and driving change.

Dr. Kiana Aran is a world-renowned bioengineer and innovator; she co-founded CRISPR QC with the mission to provide cutting-edge tools and technologies for CRISPR research and development. Dr. Aran is the inventor of the CRISPR-Chip, a groundbreaking technology that enables real-time, direct measurements of CRISPR activity that can advance sustainable agriculture and gene therapy development.

“As a female founder, I hope to inspire other women to have the courage and intellectual bravery to pursue their entrepreneurial goals,” says Dr. Aran. “The development of CRISPR-Chip technology has proven to be incredibly valuable for the CRISPR industry, and I am thrilled to see the impact of my work. This recognition from Inc. magazine is incredibly rewarding and motivates me to continue pushing boundaries in biotechnology innovations. I am excited to further bridge the gap between the benches in my academic lab and effective commercial applications.”

CRISPR QC congratulates Kiana Aran on this well-deserved recognition on Inc.’s 2023 Female Founders List and looks forward to her continued leadership.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more